Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial Autologous Mesoangioblasts for m.3243A>G Mitochondrial Myopathy
NCT05962333Phase 2Recruiting
- Sponsor
- Maastricht University
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous mesoangioblasts in mitochondrial myopathy (MM), sponsored by Maastricht University. Primary endpoints: Blood flow in left arm at Week 10, (Serious) Adverse Events at 15 weeks and 11 more. Started Aug 2023; status: recruiting.
02
Drugs
autologous mesoangioblasts
03
Conditions
mitochondrial myopathy (MM)
Beyond the preview
Go deeper on NCT05962333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05962333.